These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 12366422)

  • 21. Necrobiosis lipoidica.
    Tong LX; Penn L; Meehan SA; Kim RH
    Dermatol Online J; 2018 Dec; 24(12):. PubMed ID: 30677798
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ulcerated necrobiosis lipoidica to a teenager with diabetes mellitus and obesity.
    Pătraşcu V; Giurcă C; Ciurea RN; Georgescu CC; Ciurea ME
    Rom J Morphol Embryol; 2014; 55(1):171-6. PubMed ID: 24715184
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Photodynamic therapy of necrobiosis lipoidica--a multicenter study of 18 patients.
    Berking C; Hegyi J; Arenberger P; Ruzicka T; Jemec GB
    Dermatology; 2009; 218(2):136-9. PubMed ID: 19060464
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PUVA-gel vs. PUVA-bath therapy for severe recalcitrant palmoplantar dermatoses. A randomized, single-blinded prospective study.
    Schiener R; Gottlöber P; Müller B; Williams S; Pillekamp H; Peter RU; Kerscher M
    Photodermatol Photoimmunol Photomed; 2005 Apr; 21(2):62-7. PubMed ID: 15752122
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Refractory Ulcerated Necrobiosis Lipoidica: Closure of a Difficult Wound with Topical Tacrolimus.
    Ginocchio L; Draghi L; Darvishian F; Ross FL
    Adv Skin Wound Care; 2017 Oct; 30(10):469-472. PubMed ID: 28914682
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term successful healing of ulcerated necrobiosis lipoidica after topical therapy with becaplermin.
    Tauveron V; Rosen A; Khashoggi M; Abdallah-Lotf M; Machet L
    Clin Exp Dermatol; 2013 Oct; 38(7):745-7. PubMed ID: 23962308
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ulcerating necrobiosis lipoidica resolving in response to cyclosporine-A.
    Smith K
    Dermatol Online J; 1997 Mar; 3(1):2. PubMed ID: 9141363
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Laser and light therapies for the treatment of necrobiosis lipoidica.
    Rajabi-Estarabadi A; Aickara DJ; Hirsch M; Williams NM; Maranda EL; Van Badiavas E
    Lasers Med Sci; 2021 Apr; 36(3):497-506. PubMed ID: 32970197
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Resolution of necrobiosis lipoidica with exclusive clobetasol propionate treatment.
    Goette DK
    J Am Acad Dermatol; 1990 May; 22(5 Pt 1):855-6. PubMed ID: 2347975
    [No Abstract]   [Full Text] [Related]  

  • 30. Necrobiosis lipoidica with rapid response to doxycycline.
    Burns E; Ukoha U; Chan A
    Pediatr Dermatol; 2020 Sep; 37(5):981-982. PubMed ID: 32681529
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Successful treatment of a patient with ulcerated necrobiosis lipoidica non diabeticorum with adalimumab].
    Leister L; Körber A; Dissemond J
    Hautarzt; 2013 Jul; 64(7):509-11. PubMed ID: 23595890
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Necrobiosis lipoidica: a descriptive study of 35 cases.
    Marcoval J; Gómez-Armayones S; Valentí-Medina F; Bonfill-Ortí M; Martínez-Molina L
    Actas Dermosifiliogr; 2015 Jun; 106(5):402-7. PubMed ID: 25728565
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A comparison of psoralen plus ultraviolet A (PUVA) monotherapy, tacalcitol plus PUVA and tazarotene plus PUVA in patients with chronic plaque-type psoriasis.
    Tzaneva S; Hönigsmann H; Tanew A; Seeber A
    Br J Dermatol; 2002 Oct; 147(4):748-53. PubMed ID: 12366423
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Is the efficacy of psoralen plus ultraviolet A therapy for vitiligo enhanced by concurrent topical calcipotriol? A placebo-controlled double-blind study.
    Ermis O; Alpsoy E; Cetin L; Yilmaz E
    Br J Dermatol; 2001 Sep; 145(3):472-5. PubMed ID: 11531839
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Topical psoralen-ultraviolet A therapy for palmoplantar dermatoses: experience with 35 consecutive patients.
    Davis MD; McEvoy MT; el-Azhary RA
    Mayo Clin Proc; 1998 May; 73(5):407-11. PubMed ID: 9581579
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Large increments in psoralen-ultraviolet A (PUVA) therapy are unsuitable for fair-skinned individuals with psoriasis.
    Kirby B; Buckley DA; Rogers S
    Br J Dermatol; 1999 Apr; 140(4):661-6. PubMed ID: 10233317
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of Psoralen ultraviolet A (PUVA) photochemotherapy plus topical corticosteroids with PUVA plus bland emollients in the treatment of psoriasis.
    Tahir R; Mujtaba G
    J Ayub Med Coll Abbottabad; 2005; 17(1):34-6. PubMed ID: 15929524
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Atypical presentation of necrobiosis lipoidica in a pediatric patient.
    Özkur E; Hasçiçek SÖ; Altunay İK
    Pediatr Dermatol; 2019 Jan; 36(1):e31-e33. PubMed ID: 30506892
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Necrobiosis lipoidica.
    O'Reilly K; Chu J; Meehan S; Heller P; Ashinoff R; Gruson L
    Dermatol Online J; 2011 Oct; 17(10):18. PubMed ID: 22031644
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Psoralen loaded liposomal nanocarriers for improved skin penetration and efficacy of topical PUVA in psoriasis.
    Doppalapudi S; Jain A; Chopra DK; Khan W
    Eur J Pharm Sci; 2017 Jan; 96():515-529. PubMed ID: 27777066
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.